Author:
Chiuppesi Flavia,Wussow Felix
Reference10 articles.
1. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial;Das;Lancet Infect Dis,2023
2. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection;Wang;Sci Transl Med,2016
3. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine;Freed;Proc Natl Acad Sci USA,2013
4. Vaccine prevention of maternal cytomegalovirus infection;Pass;N Engl J Med,2009
5. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients;Plotkin;Transplantation,1994